Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 4-(((2-amino-3,5-dibromophenyl)methyl)amino)cyclohexanol
2. Abrohexal
3. Am, Bisolvon
4. Ambril
5. Ambro Puren
6. Ambro-puren
7. Ambrobeta
8. Ambrofur
9. Ambrohexal
10. Ambrols
11. Ambrolitic
12. Ambropp
13. Ambropuren
14. Ambroten
15. Ambroxin
16. Ambroxocompren
17. Bisolvon Am
18. Bromhexine Metabolite Viii
19. Bronchopront
20. Bronchowern
21. Broxol
22. Contac Husten Trunk
23. Contac Husten-trunk
24. Contac Hustentrunk
25. Dinobroxol
26. Duramucal
27. Ebromin
28. Expeflen
29. Expit
30. Farmabroxol
31. Flavamed
32. Frenopect
33. Gelopol
34. Hustenlser, Pect
35. Hustenlser, Therapin
36. Larylin Husten Lser
37. Larylin Husten-lser
38. Larylin Hustenlser
39. Lasolvan
40. Metabolite Viii, Bromhexine
41. Mibrox
42. Motosol
43. Muco Fips
44. Muco-fips
45. Mucofips
46. Mucosolvan
47. Mucotablin
48. Na 872
49. Na-872
50. Na872
51. Pdiamuc
52. Pect Hustenlser
53. Pulmonal S
54. Pulmonal, Ringelheimer
55. Ringelheimer Pulmonal
56. Sekretovit
57. Stas Hustenlser
58. Stas-hustenlser
59. Stashustenlser
60. Surbronc
61. Therapin Hustenlser
1. 18683-91-5
2. 107814-37-9
3. Rac-cis-ambroxol
4. 36557-04-7
5. Ambroxol Base
6. 4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol
7. Ambroxolum
8. Bisolvon Metabolite Viii
9. 4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol
10. Bromhexine-metabolite Viii
11. Na-872
12. Tabcin
13. Trans-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol
14. Ambroxol, Cis-
15. Cis-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol
16. Ambroxol [inn]
17. Cyclohexanol, 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-, Trans-
18. 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol
19. Trans-4-((2-amino-3,5-dibromobencil)amino)ciclohexanol
20. Trans-4-((2-amino-3,5-dibromobenzyl)amine)cyclohexanol
21. Trans-4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol
22. Qh6zt6j071
23. Cyclohexanol, 4-((2-amino-3,5-dibromobenzyl)amino)- (e)-
24. N-(2-amino-3,4-dibromocyclohexyl)-trans-4-aminocyclohexanol
25. 4-hydroxydemethylbromhexine, Cis-
26. N-(trans-4-hydroxycyclohexyl)-(2-amino-3,5-dibromobenzyl)-amine
27. N-(trans-p-hydroxycyclohexyl)-(2-amino-3,5-dibromobenzyl)amine
28. Ambroxol (inn)
29. Cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, Trans-
30. 200168s0cl
31. N-(2-amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol
32. N-(trans-4-hidroxiciclohexil)-(2-amino-3,5-dibromobencil)amina
33. Ambroxol [inn:ban]
34. Cis-4-(((2-amino-3,5-dibromophenyl)methyl)amino)cyclohexanol
35. Ambroxolum [inn-latin]
36. Cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, Cis-
37. Cyclohexanol, 4-(((2-amino-3,5-dibromophenyl)methyl)amino)-, Trans- (9ci)
38. Bromhexine Metabolite Viii
39. Ncgc00016781-04
40. Einecs 242-500-3
41. Cas-23828-92-4
42. Amboxol
43. Cis-ambroxol
44. Sr-05000001463
45. Unii-200168s0cl
46. Tabcin (tn)
47. Spectrum_001346
48. 4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexan-1-ol
49. Ambroxol [mi]
50. Rac-cis-ambroxol-[d5]
51. Prestwick0_000366
52. Prestwick1_000366
53. Prestwick2_000366
54. Prestwick3_000366
55. Spectrum2_001518
56. Spectrum3_000955
57. Spectrum4_001068
58. Spectrum5_001021
59. Trans-4-((2-amino-3,5-dibromobencil)amino)ciclohexanol [spanish]
60. N-(2-amino-3,4-dibromociclohexil)-trans-4-aminociclohexanol [spanish]
61. Ambroxol [who-dd]
62. Ec 242-500-3
63. N-(trans-4-hidroxiciclohexil)-(2-amino-3,5-dibromobencil)amina [spanish]
64. Unii-qh6zt6j071
65. Oprea1_766685
66. Schembl18702
67. Bspbio_000491
68. Kbiogr_001396
69. Kbioss_001826
70. Mls001306470
71. Divk1c_000027
72. Schembl423712
73. Spbio_001595
74. Spbio_002412
75. Bpbio1_000541
76. Chembl153479
77. Schembl7855003
78. 4-[(2-amino-3,5-dibromo-phenyl)methylamino]cyclohexanol
79. Chembl1477775
80. Dtxsid8022583
81. Schembl21765132
82. Bcbcmap01_000092
83. Chebi:92994
84. Gtpl10692
85. Kbio1_000027
86. Kbio2_001826
87. Kbio2_004394
88. Kbio2_006962
89. Kbio3_002050
90. Dtxsid60860228
91. Chebi:135590
92. Ninds_000027
93. Cyclohexanol, 4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-
94. Hms2089d06
95. Hms2231b19
96. Hms3373j22
97. Hms3886m18
98. Zinc587613
99. Albb-022461
100. Bcp04489
101. Hy-b1039
102. Bbl009896
103. Bdbm50395322
104. Mfcd00242702
105. Mfcd28143339
106. S5710
107. Stk711075
108. Akos005530704
109. Akos015889660
110. Akos027338704
111. Zinc100001905
112. Zinc100070274
113. Ac-8362
114. Ambroxol Hydrochloride Impurity D [ep]
115. Bcp9000283
116. Ccg-207907
117. Cs-4558
118. Db06742
119. Sb17463
120. Sb82866
121. Idi1_000027
122. Smp1_000014
123. Ncgc00016781-01
124. Ncgc00016781-02
125. Ncgc00016781-08
126. Ncgc00159399-02
127. Ncgc00371077-02
128. As-56023
129. Smr000718792
130. Vs-02240
131. 4-hydroxydemethylbromhexine, Trans-
132. Bcp0726000066
133. Sbi-0051766.p002
134. Ab00514663
135. Cs-0323348
136. Ft-0622261
137. Ft-0630430
138. Ft-0661549
139. D07442
140. 4-(2-amino-3,5-dibromobenzylamino)cyclohexanol
141. Ab00053639_13
142. Ab01275465-01
143. 683a915
144. A813089
145. Q221637
146. Sr-05000001463-1
147. Ambroxol Hydrochloride Impurity D [ep Impurity]
148. Brd-k11223672-003-03-7
149. Brd-k11223672-003-04-5
150. Brd-k56558538-003-02-8
151. 4-[(2-amino-3,5-dibromophenyl)methylamino-]cyclohexanol
152. 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexanol
153. (1s,4s)-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexanol
154. 4-[(2-amino-3,5-dibromobenzyl)amino]cyclohexanol, Trans-
155. (1r,4r)-4-((2-amino-3,5-dibromobenzyl)amino)cyclohexan-1-ol
156. Trans-4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexanol
157. Cyclohexanol, 4-[[(2-amino-3,5-dibromo-phenyl)methyl]amino]-, Trans
| Molecular Weight | 378.10 g/mol |
|---|---|
| Molecular Formula | C13H18Br2N2O |
| XLogP3 | 2.6 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Exact Mass | 377.97654 g/mol |
| Monoisotopic Mass | 375.97859 g/mol |
| Topological Polar Surface Area | 58.3 Ų |
| Heavy Atom Count | 18 |
| Formal Charge | 0 |
| Complexity | 259 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Ambroxol is indicated for secretolytic therapy in bronchoplmonary disease with abnormal mucus secretion and transport. It allows the mucus to be more easily cleared and ease a patient's breathing.
Expectorants
Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. (See all compounds classified as Expectorants.)
R05CB06
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
R - Respiratory system
R05 - Cough and cold preparations
R05C - Expectorants, excl. combinations with cough suppressants
R05CB - Mucolytics
R05CB06 - Ambroxol
Absorption
Rapid and almost complete.
Ambroxol has known human metabolites that include 2-Amino-3,5-dibromobenzaldehyde and 4-Aminocyclohexanol, cis-.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
7-12 hours
Ambroxol is a mucolytic agent. Excessive Nitric oxide (NO) is associated with inflammatory and some other disturbances of airways function. NO enhances the activation of soluble guanylate cyclase and cGMP accumulation. Ambroxol has been shown to inhibit the NO-dependent activation of soluble guanylate cyclase. It is also possible that the inhibition of NO-dependent activation of soluble guanylate cyclase can suppress the excessive mucus secretion, therefore it lowers the phlegm viscosity and improves the mucociliary transport of bronchial secretions.
API SUPPLIERS
Atman Pharmaceuticals: A One Stop Solution Provider to All Your API Needs.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
Atman Pharmaceuticals: A One Stop Solution Provider to All Your API Needs.
About the Company : Atman Pharmaceuticals is a fully integrated pharmaceutical company that has distinguished itself as a leader in Bulk Drugs (API) marketing both domestically in India and overseas. ...
About the Company : APIPL is a fully-integrated Indian pharmaceutical company manufacturing APIs for various segments. We are one of the quality manufacturers and suppliers of over a dozen APIs. These...
About the Company : The Bakul Group of companies headquartered in Mumbai, India are engaged in the development and manufacture of high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, ...
About the Company : In the dinamic pharmaceutical field, DEAFARMA is the reference point for primaries Pharmaceutical Laboratories for over twenty years, even in the national and international territo...
About the Company : Established in 1995, Globalchem India was founded with the mission of catering to the global community. Since its inception, our primary focus has been to supply pharmaceutical ing...
About the Company : Osmopharm S.A. is a GMP approved pharmaceutical company located in Switzerland and specialized in development and production of modified release solid oral form drugs under contrac...
About the Company : RA Chem Pharma Limited is a vertically integrated pharmaceutical company.Over the past 10 years, it has expanded its spectrum by establishing state-of-the-art manufacturing facilit...
About the Company : S.S. PHARMACHEM is a professionally managed Bulk Drug & Chemical manufacturing unit headed by MR. SAGAR S. SANGEKAR & MR. SANJAY S. SANGEKAR. Established in 1987 & committed to dev...
About the Company : Incepted in 1989, Zim has made a significant mark as a maverick pharma innovator. Throughout all these years constantly penetrating newer areas of pharmaceutical technology and bus...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
2-Amino-3,5-dirbomobenzaldehyde
CAS Number : 50910-55-9
End Use API : Ambroxol
About The Company : The division was established in 1981 as a Specialty Chemicals Division with a focus to manufacture specialty chemicals and pharmaceutical intermediates. In Apri...
CAS Number : 27489-62-9
End Use API : Ambroxol
About The Company : We are a top producer of Pharmaceutical Intermediates, Specialty Chemicals, and More, with origins dating back to 1998. Globally renowned for its Organic Compou...
2-Amino-3,5-Dibromo Benzaldehyde [Adba]
CAS Number : 50910-55-9
End Use API : Ambroxol
About The Company : We are a top producer of Pharmaceutical Intermediates, Specialty Chemicals, and More, with origins dating back to 1998. Globally renowned for its Organic Compou...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Italy
Brand Name : Ambroxol
Dosage Form :
Dosage Strength : The Scir 200 Ml 0.3%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : Surfactal
Dosage Form :
Dosage Strength : 1 Bottle Ev 1G 50 Ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Ukraine
Brand Name : Product Under Development
Dosage Form : Tablet
Dosage Strength : 30MG; 200MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ukraine
Regulatory Info :
Registration Country : Ukraine
Brand Name : Product Under Development
Dosage Form : Syrup
Dosage Strength : 3MG/ML
Packaging : 100ML
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ukraine
Regulatory Info :
Registration Country : Ukraine
Brand Name : Product Under Development
Dosage Form : Syrup
Dosage Strength : 6MG/ML
Packaging : 100ML
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Ukraine
Regulatory Info : EU CTD Dossier- 2 Sem 2017
Registration Country : Portugal
Brand Name :
Dosage Form : Syrup
Dosage Strength : 6MG/1ML
Packaging : 1 Bottle- 125 ML, 250 ML
Approval Date :
Application Number :
Regulatory Info : EU CTD Dossier- 2 Sem 2017
Registration Country : Portugal
Regulatory Info : EU CTD Dossier- 2 Sem 2017
Registration Country : Portugal
Brand Name :
Dosage Form : Syrup
Dosage Strength : 3MG/1ML
Packaging : 1 Bottle- 200 ML
Approval Date :
Application Number :
Regulatory Info : EU CTD Dossier- 2 Sem 2017
Registration Country : Portugal
Regulatory Info :
Registration Country : Italy
Brand Name : Tauxolo
Dosage Form :
Dosage Strength : The Scir 200 Ml 0.3%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Broxol
Dosage Form :
Dosage Strength : The Scir 150 Ml 0.3%
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Broxol
Dosage Form :
Dosage Strength : To 30 Bust Groun Os 30 Mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
APIs
Reply
24 Jul 2023
Reply
23 Mar 2023
Reply
28 Sep 2022
Reply
26 Jan 2022
Reply
31 May 2021
Reply
04 Aug 2020
Reply
03 Nov 2018
Reply
16 Oct 2018
Reply
08 Jul 2017
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Comment (6)
